Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib.
Zhao J, Lin G, Zhuo M, Fan Z, Miao L, Chen L, Zeng A, Yin R, Ou Y, Shi Z, Yin J, Gao W, Chen J, Zhou X, Zeng Y, Liu X, Xu H, Chen R, Xia X, Carbone DP.
Zhao J, et al. Among authors: chen j, chen l, chen r.
Lung Cancer. 2020 Mar;141:114-118. doi: 10.1016/j.lungcan.2019.10.021. Epub 2019 Nov 25.
Lung Cancer. 2020.
PMID: 31839416
Free PMC article.